ROIVANT SCIENCES LTD. Operating Lease Right-of-Use Assets
ROIVANT SCIENCES LTD. (ROIV) had Operating Lease Right-of-Use Assets of $78.89 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $78.89M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $80.42M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $83.56M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $85.14M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $78.89M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $80.42M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $83.56M 10-Q · filed 2026-02-06 | |
| 2025-09-30 | $85.14M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $87.08M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $89.02M 10-K · filed 2026-05-20 | |
| 2024-12-31 | $90.89M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $42.98M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $45.31M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $44.00M 10-K · filed 2025-05-29 | $46.89M 10-K · filed 2024-05-30 |
| 2023-12-31 | $46.90M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $48.63M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $51.63M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $53.25M 10-K · filed 2024-05-30 | |
| 2022-12-31 | $54.64M 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $53.09M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $59.43M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $61.04M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $61.68M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $63.20M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $65.16M 10-Q · filed 2021-09-21 | |
| 2021-03-31 | $62.28M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |